Vivera Pharmaceuticals Licenses TABMELT®, a Sublingual Pharmaceutical Drug-Delivery System for Cannabidiol (CBD)
Wednesday, May 01, 2019
Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, today announces the debut of TABMELT®, a sublingual drug delivery system that Vivera has exclusively licensed for the specific use for pharmaceutical cannabinoids, including cannabidiol (CBD), a non-psychoactive compound derived from hemp, and other hemp-derived and biosynthetic cannabinoid compounds.
“According to the Centers for Disease Control and Prevention, on average, 130 Americans die every single day from an opioid overdose,” said Dr. Jon Norman, Chief Scientific Officer at Vivera. “We believe CBD has several important roles to play in this national crisis. It may offer a non-addictive way to manage pain and may create an alternative to starting patients on opioids in the first place. In addition, it may hold promise as a way to ease the detox process for patients in drug or alcohol recovery.”
Internationally patented and U.S. patent-pending TABMELT® may optimize the pharmaceutical delivery of CBD by offering a sublingual, set-dose system, which may enhance bioavailability by largely avoiding first-pass metabolism through the liver.
“Vivera’s commitment to innovative research, product development, and providing non-addictive therapies and treatments to patients is the foundation of our work,” said Olivia Karpinski, Co-founder and Executive Vice President of Vivera. “Our goal is to provide a non-addictive solution to patients nationwide who seek to manage pain and opioid cessation and deterrence in a safer way.”
Vivera is headquartered in Newport Beach, California.
